#China #Xi'an #KHB #Polaris V150 #Chemiluminescence

KHB's Innovation at MEDICA 2025

At the MEDICA 2025 event, Shanghai Kehua Bio-engineering Co., Ltd. (KHB) has taken a significant leap in the world of in vitro diagnostic (IVD) solutions by introducing their latest compact platform — the automatic chemiluminescent immunoassay analyzer Polaris V150. This state-of-the-art analyzer is engineered to cater to the needs of small to medium-sized laboratories, as well as offering STAT testing capabilities for large hospitals and third-party laboratories. The Polaris V150 represents KHB's commitment to delivering innovative solutions in automated diagnostics.

Compact Design Meets High Efficiency

The Polaris V150 stands out for its compact footprint of just 0.36 square meters, yet it boasts an impressive capability of executing 150 tests per hour. This feature ensures that even laboratories with limited space can achieve high operational efficiency. The analyzer is designed for continuous sample, reagent, and reaction cup insertion, which streamlines workflows. Notably, it prioritizes urgent samples through a STAT function, enhancing the speed of clinical decision-making.

Equipped with 40 sample positions, the device supports both serum and plasma storage and incorporates automatic dilution features. Additionally, it enhances reliability with comprehensive detection for liquid levels, clots, and anti-collision measures.

Precision with ALP-AMPPD Technology

The Polaris V150 is powered by a high-performance chemiluminescence system, ALP-AMPPD, which guarantees exceptional precision and accuracy (CV < 3%) for all tests. It employs an all-in-one reagent kit arrangement that includes calibrators with embedded QR code information for streamlined operations. This innovative approach simplifies reagent management and promotes standardized usage across laboratories.

The analyzer also boasts a diverse and continually expanding reagent portfolio with over 60 tests across 10 major disease panels. This range includes tests for thyroid function markers, sex hormones, tumor markers, infectious diseases, cardiac markers, inflammation indicators, glycometabolism, anemia, bone metabolism, and more.

Enhanced User Experience

Beyond analytical performance, the Polaris V150 features an intelligent system design that significantly improves usability in laboratories. It offers real-time monitoring of reagent and consumable status, providing laboratories with ongoing insights into their operational readiness. The intuitive user interface, paired with a built-in touchscreen, facilitates efficient navigation and simplifies controls, thus lowering training requirements and enhancing overall user satisfaction.

Reliability and Smart Maintenance

To ensure continuous high-quality performance, the analyzer is equipped with a built-in cooling system that operates at 2–8°C for up to 12 reagent positions. This feature guarantees optimal reagent stability, while functions like remote monitoring and automatic maintenance minimize downtime and simplify servicing, enabling laboratories to maintain high operational continuity.

A Major Attraction at MEDICA 2025

During MEDICA 2025, the Polaris V150 became a central highlight at the KHB booth, drawing international partners seeking compact yet high-performance immunotesting solutions. Live demonstrations and technical consultations by KHB’s expert team provided attendees with comprehensive insights into the device's capabilities, showcasing its suitability for both routine and emergency laboratory environments.

"The interest we've garnered at MEDICA reflects a strong demand for compact, high-quality chemiluminescent systems like the Polaris V150," stated KHB's product manager. "We are excited to share this innovation with our global partners and deliver effective immunotesting solutions to laboratories worldwide."

About KHB Group

Shanghai Kehua Bio-engineering Co., Ltd. (KHB, stock code 002022.SZ) specializes in in vitro diagnostics, presenting a comprehensive range of medical diagnostic products focused on immunodiagnostics, biochemical diagnostics, molecular diagnostics, and point-of-care testing (POCT). Since its inception in 1981, KHB has evolved into a high-tech enterprise integrating research and development, production, and marketing operations. The company was listed on the Shenzhen Stock Exchange in 2004. For more information, please visit KHB's official website or follow them on their social media channels.